We are live on
!
Find out more
RSCM
Rock Springs Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
93.03%
This Fund
S&P 500
This Quarter
Est. Return
+15.79%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$280M
AUM Growth
–
Cap. Flow
+$264M
Cap. Flow
% of AUM
94.32%
Top 10 Holdings %
Top 10 Hldgs %
44.86%
Holding
69
New
69
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$19.8M |
| 2 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$19.8M |
| 3 |
Biogen
BIIB
|
+$13.7M |
| 4 |
AbbVie
ABBV
|
+$11.1M |
| 5 |
THOR
THORATEC CORPORATION
THOR
|
+$10.8M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 72.98% |
| 2 | Financials | 1.53% |
| 3 | Industrials | 0.94% |
| 4 | Technology | 0.35% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HTWR
26
DELISTED
HEARTWARE INTERNATIONAL INC COM STK (DE)
HTWR
| $3.08M | 1.1% |
+32,750
| New | +$2.77M |
|
|
OREX
27
DELISTED
Orexigen Therapeutics, Inc.
OREX
| $2.96M | 1.06% |
+52,500
| New | +$2.95M |
|
28
Pacira BioSciences
PCRX
$997M
| $2.9M | 1.04% |
+50,500
| New | +$2.66M |
|
29
Edwards Lifesciences
EW
$51.7B
| $2.79M | 1% |
+255,000
| New | +$2.87M |
|
|
AEGR
30
DELISTED
Aegerion Pharmaceuticals
AEGR
| $2.79M | 1% |
+39,250
| New | +$3M |
|
31
HCA Healthcare
HCA
$89.5B
| $2.77M | 0.99% |
+58,000
| New | +$2.68M |
|
|
ATHN
32
DELISTED
Athenahealth, Inc.
ATHN
| $2.62M | 0.94% |
+19,500
| New | +$2.51M |
|
|
TRNX
33
DELISTED
TORNIER N V SHARES (NLD)
TRNX
| $2.44M | 0.87% |
+130,000
| New | +$2.45M |
|
34
Universal Health Services
UHS
$10.5B
| $2.32M | 0.83% |
+28,500
| New | +$2.28M |
|
35
Innoviva
INVA
$1.48B
| $2.25M | 0.8% |
+78,183
| New | +$2.29M |
|
|
CVD
36
DELISTED
COVANCE INC.
CVD
| $2.25M | 0.8% |
+25,500
| New | +$2.21M |
|
|
FEIC
37
DELISTED
FEI COMPANY
FEIC
| $2.19M | 0.78% |
+24,500
| New | +$2.17M |
|
38
Incyte
INCY
$24.4B
| $2.1M | 0.75% |
+41,500
| New | +$1.81M |
|
|
AUXL
39
DELISTED
AUXILIUM PHARAMCEUTICALS INC
AUXL
| $2.07M | 0.74% |
+100,000
| New | +$1.89M |
|
40
Cooper Companies
COO
$14.5B
| $2.04M | 0.73% |
+66,000
| New | +$2.1M |
|
|
FRX
41
DELISTED
FOREST LABORATORIES INC
FRX
| $2.04M | 0.73% |
+34,000
| New | +$1.71M |
|
|
PCYC
42
DELISTED
PHARMACYCLICS INC
PCYC
| $1.96M | 0.7% |
+18,500
| New | +$2.25M |
|
|
CERN
43
DELISTED
Cerner Corp
CERN
| $1.9M | 0.68% |
+34,000
| New | +$1.91M |
|
|
ITMN
44
DELISTED
INTERMUNE INC
ITMN
| $1.84M | 0.66% |
+125,000
| New | +$1.73M |
|
45
Pediatrix Medical
MD
$2.2B
| $1.71M | 0.61% |
+32,000
| New | +$1.72M |
|
46
Jazz Pharmaceuticals
JAZZ
$16.7B
| $1.65M | 0.59% |
+13,000
| New | +$1.35M |
|
|
TSRO
47
DELISTED
TESARO, Inc.
TSRO
| $1.65M | 0.59% |
+58,250
| New | +$2.16M |
|
48
Viatris
VTRS
$18.9B
| $1.58M | 0.57% |
+36,500
| New | +$1.5M |
|
49
Cencora
COR
$61.2B
| $1.58M | 0.57% |
+22,500
| New | +$1.51M |
|
|
ABCO
50
DELISTED
Advisory Board Co
ABCO
| $1.56M | 0.56% |
+24,500
| New | +$1.56M |
|
Similar funds
ACM
BCM
PP
GAM
FACM
RMC
JIP
II
Rock Springs Capital Management's Q4 2013 Portfolio in Review
Q4 2013 is the first quarter with a 13F filing on record for Rock Springs Capital Management, which disclosed 69 positions worth $280M. Its ten largest holdings account for 45% of the portfolio.
Its largest position is Gilead Sciences: 285,000 shares worth $21.4M.
By sector, the portfolio is most concentrated in Healthcare at 73% of assets, followed by Financials and Industrials.
- Rock Springs Capital Management's largest Q4 2013 buy was Gilead Sciences: 285,000 shares worth $21.4M.
- Rock Springs Capital Management's ten largest holdings make up 45% of its $280M portfolio in Q4 2013.
- Rock Springs Capital Management disclosed 69 positions in Q4 2013, its first 13F filing on record.
Based on Rock Springs Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.